Overview

Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether on course (6 cycles) of consolidation therapy with Revlimid can shrink or slow the growth of Chronic Lymphocytic Leukemia (CLL) in the bone marrow.
Phase:
Phase 2
Details
Lead Sponsor:
Thomas Kipps
Collaborator:
Celgene Corporation
Treatments:
Lenalidomide
Thalidomide